Eisai Co., Ltd. has announced the launch of its in-house developed anti-insomnia drug DAYVIGO® (lemborexant) in China, offering patients a new treatment option that works through a novel mechanism to address sleep disorders. Approved on May 27, 2025, DAYVIGO is indicated for adults with insomnia characterized by difficulty falling asleep or maintaining sleep. The introduction … China Approves Eisai’s DAYVIGO®: A First-in-Class Sleep Medicine Targeting Orexin Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.